Clinical trials: Histological Type of Neoplasm
Advanced Hematological Disorders
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
Part 1 will be conducted as an open-label, non-randomized, non-placebo-controlled dose escalation study using pre-specified doses.
- Trial name
- NCT03048344
- Testing
- ORH-2014
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Orsenix LLC
Leukemia
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098436
- Testing
- laromustine, temozolomide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vion Pharmaceuticals
Renal Cell Carcinoma
Study of CP-461 in Patients With Advanced Renal Cell Cancer
The purpose of this study is to determine the efficacy of CP-461 given twice-daily orally in locally advanced or metastatic renal cell cancer and to evaluate the safety profile of CP-461 in this patient population.
- Trial name
- NCT00036036
- Testing
- CP-461
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Inc
Multiple Myeloma
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
The study evaluated the safety of Lenalidomide monotherapy in participants with advanced multiple myeloma who had discontinued treatment with combination thalidomide plus high-dose dexamethasone or high-dose dexamethasone alone…
- Trial name
- NCT00622336
- Testing
- CC-5013, Lenalidomide
- Where
- 7 sites in Russia, Ukraine
- Volunteers
- 330 people
- Sponsor
- Celgene
Recurrent Glioblastoma Multiforme (GBM)
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
This was an investigational study to assess the objective overall response (OOR) rate (complete response [CR] + partial response [PR]) of imatinib mesylate and hydroxyurea (hydroxycarbamide) combination therapy in patients with…
- Trial name
- NCT00290771
- Testing
- Imatinib tablets, Hydroxyurea capsules
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- Novartis
Diffuse Large B Cell Lymphoma
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
To explore the efficacy and safety of TQB2825 injection combined immunochemotherapy in subjects with untreated or R/R DLBCL. The efficacy evaluation indicators are objective response rate (ORR), complete response rate (CR…
- Trial name
- NCT06829771
- Testing
- TQB2825 injection +R-CHOP regimen, TQB2825 injection + GemOx
- Where
- 25 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-Hodgkin Lymphoma
PIC1 Injection Therapy for Relapsed/Refractory B-NHL
This is an investigator-initiated trial aimed at assessing the safety and efficacy of PIC1 injection in the treatment of relapsed/refractory B-cell Non-Hodgkin Lymphoma.
- Trial name
- NCT07456371
- Testing
- PIC1 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Malignant Melanoma
Neoadjuvant L19IL2/L19TNF- Pivotal Study
Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.
- Trial name
- Pivotal (NCT02938299)
- Testing
- L19IL2 + L19TNF, Surgery
- Where
- 22 sites in France, Germany and 2 more
- Volunteers
- 214 people
- Sponsor
- Philogen S.p.A.
Colorectal Neoplasms
Third Eye Retroscope Randomized Clinical Evaluation
The Third Eye® Retroscope® is a device that can be inserted through the instrument channel of a standard colonoscope to provide an additional, retrograde (or backward) view that reveals areas behind folds and flexures in the…
- Trial name
- TERRACE (NCT01044732)
- Testing
- Third Eye Retroscope
- Where
- 9 sites in United States, Belgium and 3 more
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- Avantis Medical Systems
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with…
- Trial name
- NCT05342636
- Testing
- Pembrolizumab, Coformulation favezelimab/pembrolizumab, MK-4830
- Where
- 46 sites in Brazil, Chile and 11 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Renal Cell Carcinoma
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
The primary purpose is to monitor the safety and tolerability and effectiveness of sunitinib malate in the treatment of patients with metastatic renal cell carcinoma and gastrointestinal stromal tumor among filipino patients in…
- Trial name
- NCT01073644
- Testing
- Sunitinib malate
- Where
- 2 sites in Philippines
- Volunteers
- 3 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia
Alvocidib Biomarker-driven Phase 2 AML Study
The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete Remission) of ACM (Alvocidib/Cytarabine/Mitoxantrone) compared to CM (Cytarabine/Mitoxantrone) treatment in refractory or relapsed AML…
- Trial name
- NCT02520011
- Testing
- Alvocidib, Cytarabine, Mitoxantrone
- Where
- 38 sites in United States, Canada and 2 more
- Volunteers
- 104 people
- Sponsor
- Sumitomo Pharma America, Inc.
Malignant Melanoma
A Study of RO5185426 in Patients With Metastatic Melanoma
This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.
- Trial name
- NCT01248936
- Testing
- RO5185426
- Where
- 28 sites in United States
- Volunteers
- 374 people
- Sponsor
- Hoffmann-La Roche
Merkel Cell Carcinoma, Basal Cell Carcinoma
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
The purpose of this study is to assess the safety and efficacy of RP1 (administered into the tumor) in 90 patients who have received an organ transplant in the past and currently have skin cancer.
- Conditions
- Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
- Trial name
- ARTACUS (NCT04349436)
- Testing
- RP1, intra-tumoral injection, oncolytic virus
- Where
- 24 sites in United States
- Volunteers
- 69 people
- Sponsor
- Replimune, Inc.
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00014664
- Testing
- apolizumab
- Where
- United States
- Sponsor
- PDL BioPharma, Inc.
AML and High Risk MDS
A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
This study will assess the safety and preliminary efficacy of escalating doses of LGH447 monotherapy in AML and MDS and LGH447 in combination with midostaurin in AML.
- Trial name
- NCT02078609
- Testing
- LGH447, LGH447 + midostaurin
- Where
- 9 sites in United States, Australia and 5 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
This Phase I clinical trial will evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of 8 mg ITI-1001 in participants with newly diagnosed glioblastoma (GBM).
- Trial name
- NCT05698199
- Testing
- ITI-1001
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Immunomic Therapeutics, Inc.
Lymphoma, Malignant, Hodgkin's Lymphoma
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.
- Conditions
- Lymphoma, Malignant, Hodgkin's Lymphoma, B Cell Lymphoma
- Trial name
- NCT00741871
- Testing
- SB1518
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- S*BIO
Pregnancy Related, Pregnancy Complications
MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy
This is a retrospective cohort study that will be conducted using secondary de-identified electronic healthcare data (EHD) that originally were collected for the purposes of health insurance billing and/or routine patient care…
- Conditions
- Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
- Trial name
- NCT05739136
- Testing
- Relugolix + Estradiol + Norethindrone Acetate
- Where
- United States
- Volunteers
- 530 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Hepatosplenic T-cell Lymphoma
Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands
The purpose of this study is to examine reports of the cancer called hepatosplenic T-cell lymphoma (HSTCL) in the Dutch National Database of Pathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief or PALGA) during…
- Trial name
- NCT00731536
- Testing
- No intervention
- Where
- 10 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.